

***The GOG Highlight Reel:
An Education Series Highlighting Newsworthy Data Distillation
and Emerging Global Therapies in Clinical Trials
July 26, 2025
Washington, DC***

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** *(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An "ineligible company" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

| NAME | Individual's Role(s) in Activity | Nothing To Disclose | Name of Ineligible Company(s) | Nature of Relevant Financial Relationship(s) |
|------------------------------------|----------------------------------|---------------------|---|---|
| <i>Planning Disclosures</i> | | | | |
| Thomas Herzog, MD | Planner/ Moderator | | Astra Zeneca; Caris; Clovis; Eisai; Epsilon; Genentech; GSK; J&J; Merck; Mersana; Novocure; Seattle Genetics | Scientific Advisory Boards |
| Bradley Monk, MD | Planner/ Moderator | | Acrivon Adaptimmune ; Agenus; Akeso Bio; Amgen; AstraZeneca; Biohaven; BMS; Corcept; Eisai; Eli Lilly; Genmab; Seagen; Pfizer; Genalux; GOG Foundation; Gradalis; GSK; HengRui; Immunogen; Abbvie; Karyopharm; lovance; Merck; Mersana; Mural; Alkermes; Myriad; Novartis; Novocure; OncoC4; Panavance; Profound Bio; Regeneron; Roche; Genentech; Sutro; Verastem; Zentalis; Zymeworks | Consultant (Acrivon Adaptimmune ; Agenus; Akeso Bio; Amgen; AstraZeneca; Biohaven; BMS; Corcept; Eisai; Eli Lilly; Genmab; Seagen; Pfizer; Genalux; GOG Foundation; Gradalis; GSK; HengRui; Immunogen; Abbvie; Karyopharm; lovance; Merck; Mersana; Mural; Alkermes; Myriad; Novartis; Novocure; OncoC4; Panavance; Profound Bio; Regeneron; Roche; Genentech; Sutro; Verastem; Zentalis; Zymeworks) Speaker (AstraZeneca; Eisai; GSK; Immunogen; Abbvie; Merck) |
| <i>Speaker Disclosures</i> | | | | |
| Duska, Linda, MD | Speaker | | Regeneron; Aadi Bioscience; Daiichi Sankyo; Agenus; NX Development Corp | Advisory Board (Regeneron; Aadi Bioscience; Daiichi Sankyo) Data Safety Monitoring -Money to institution (Agenus) NX Development Corp |

| | | | | |
|-------------------------|----------------|--|---|--|
| Eskander, Ramez, MD | Speaker | | AstraZeneca, MSD, Regeneron, PMV Pharmaceuticals, Daiichi Sanyo, GSK, Myriad, Seagen, Abbvie, Pfizer, Novocure, BioNTech, Eisai, Roche, Mersana; Nuvectis Pharma, Merck, Loxo @ Lilly, Genmab/Seagen, Clovis Oncology, Acrivon therapeutics, Zentalis, Eisai, Gilead, Roche | Consultant (AstraZeneca, MSD, Regeneron, PMV Pharmaceuticals, Daiichi Sanyo, GSK, Myriad, Seagen, Abbvie, Pfizer, Novocure, BioNTech, Eisai, Roche, Mersana) Research Funding (Nuvectis Pharma, GSK, Merck, Daiichi Sankyo, Loxo @ Lilly, AstraZeneca, Genmab/Seagen, Clovis Oncology, Acrivon Therapeutics, Zentalis, Eisai, Gilead, Roche) |
| Kathleen Moore, MD | Speaker | | Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation; GOG Partners; NRG Ovarian Committee Chair; Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmaceuticals; GSK/Tesaro; Duality Biologics; Artios; Amgen; Schrodinger; Daiichi Sankyo/Lilly; Regeneron; Up to Date; BioNTech SE | Honoraria (Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation Leadership (GOG Partners; NRG Ovarian Committee Chair) Consulting or Advisory Role (Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmaceuticals; GSK/Tesaro; Duality Biologics; Schrodinger) Research Funding (Merck; Regeneron; Verastem; AstraZeneca; Immunogen; Artios; Amgen; Daiichi Sankyo/Lilly; Immunocore) Patents, Royalties, Other Intellectual Property (Up to Date) Travel, Accommodations, Expenses (BioNTech SE) |
| Robert Coleman, MD | Speaker | | Mural; AstraZeneca; Pharma&; Eisai; Genentech USA Inc; GSK; Gradalis; Mersana; Novocure; Abbvie; Immunogen, Abbvie; Merck; Novrtis; Valero/Valbio; Seagen/Genmab/Pfizer; VBL; Eisai; GOG-Partners; Karyopharm | Consultant (Mural; AstraZeneca; Pharma&; Eisai; Genentech USA Inc; GSK; Gradalis; Mersana; Novocure; Seagen/Genmab/Pfizer) Grant Contract (Genentech USA Inc; Abbvie; Immunogen, Abbvie; Merck; Novrtis; Valero/Valbio; Seagen/Genmab/Pfizer; Karyopharm) Data & Safety Monitoring (VBL; Eisai; GOG-Partners) |
| Olawaiye, Alexander, MD | Speaker | | AstraZeneca; GSK; Merck; Daiichi Sankyo | Advisory Board |
| David O'Malley, MD | Speaker | | AbbVie; AdaptImmune; Advaxis; Agenus, Inc; Alkermes; Aravive, Inc.; Arcus Biosciences, Inc.; Arquer Diagnostics; AstraZeneca; Atossa Therapeutics; BeiGene USA, Inc.; Boston Biomedical; Bristol Myers Squibb; Cardiff Oncology; Celcuity; Clovis Oncology; Corcept Therapeutics; Deciphera Pharma; Duality Bio; Eisai; Elevar; EMD Serono, Inc.; Exelixis; Genentech Inc; Genmab; Genelux; GlaxoSmithKline; | Institution Received Funds for research (AbbVie; Advaxis; Agenus, Inc; Alkermes; Aravive, Inc.; Arcus Biosciences, Inc.; AstraZeneca; BeiGene USA, Inc.; Boston; Biomedical; Bristol Myers Squibb; Clovis Oncology; Deciphera Pharma; Eisai; EMD Serono, Inc.; Exelixis; Genentech Inc; Genmab; GlaxoSmithKline; GOG Foundation; Hoffmann-La Roche Inc; ImmunoGen, Inc; Incyte Corporation; IOVANCE |

| | | | | |
|-------------------------|-----------------------|----------|--|--|
| | | | GOG Foundation; Hoffmann-La Roche Inc; ImmunoGen, Inc; Imvax; InterVenn; INXMED; Incyte Corporation; IOVANCE Biotherapeutics; Jazz Pharmaceuticals; Karyopharm; Laekna; Leap Therapeutics, Inc.; Ludwig Institute for Ca; Luzsana Biotechnology; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Myriad; NCI; Novartis; NovoCure; NRG Oncology; OncoC4, Inc.; OncoQuest Inc.; Onconova; Pfizer Inc; Precision Therapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc; RTOG; Rubius Therapeutics; ReplImmune; R Pharm; Roche Diagnostics; Seattle Genetics (SeaGen); Sorrento; Sutro Biopharma; SWOG; ; Tarveda Therapeutics; Toray; Trillium; Umoja; Verastem, Inc; VBL Therapeutics; Vincerx Pharma; Xencor; Zentalis | Biotherapeutics; Karyopharm; Leap Therapeutics, Inc.; Ludwig Institute for Ca; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; NCI; Novartis; NovoCure; NRG Oncology; OncoC4, Inc.; OncoQuest Inc.; Pfizer Inc; Precision Therapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc; RTOG; Rubius Therapeutics; Seattle Genetics (SeaGen); Sutro Biopharma; SWOG; Verastem, Inc) Ad Board/Consultant (AbbVie; AdaptImmune; Agenus, Inc; Arquer Diagnostics; Arcus Biosciences, Inc.; AstraZeneca; Atossa Therapeutics; Boston Biomedical; Cardiff Oncology; Celcuity; Clovis Oncology; Corcept Therapeutics; Duality Bio; Eisai; Elevar; Exelixis; Genentech Inc; Genelux; GlaxoSmithKline; GOG Foundation; Hoffmann-La Roche Inc; ImmunoGen, Inc; Imvax; InterVenn; INXMED; Jazz Pharmaceuticals; Laekna; Leap Therapeutics, Inc.; Luzsana Biotechnology; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Myriad; Novartis; NovoCure; OncoC4, Inc.; Onconova; Regeneron Pharmaceuticals, Inc; ReplImmune; R Pharm; Roche Diagnostics; Seattle Genetics (SeaGen); Sorrento; Sutro Biopharma; Tarveda Therapeutics; Toray; Trillium; Umoja; Verastem, Inc; VBL Therapeutics; Vincerx Pharma; Xencor; Zentalis |
| Bhavana Pothuri, MD, MS | Speaker | | AstraZeneca; celsion/Immunon; Clovis Oncology, Inc.; Genentec; Eisai; GlaxoSmithKline; GOG foundation; Imab; Immunogen; Incyte Corporation; Karyopharm Therapeutics; Merck; Mersana; Seagen Inc.; Sutro; Toray Industries | Consultant (AstraZeneca; Eisai; GlaxoSmithKline; GOG foundation; Merck; Mersana; Seagen Inc.; Sutro) Grant/Contract (AstraZeneca; celsion/Immunon; Clovis Oncology, Inc.; Genentec; GlaxoSmithKline; Imab; Immunogen; Incyte Corporation; Karyopharm Therapeutics; Merck; Mersana; Seagen Inc.; Sutro; Toray Industries) |
| Leslie Randall, MD | Speaker | | AstraZeneca; Genmab; Pfizer; GSK; Eisai; Merck; AbbVie; GOG Foundation | Consultant (AstraZeneca; Genmab; Pfizer; GSK; Eisai; Merck; Abbvie; GOG Foundation) Research Funding (Merck; AbbVie; GOG Foundation) |
| Brian Slomovitz, MD | Speaker | | Seagen, Novocure; AstraZeneca; Aadi; Regeneron; Immunocore; Merck; Gilead, Eisai; Incyte | Consultant |
| | | | | |
| Holley Engbert | Staff | X | | |
| Heather Rush | Staff | X | | |
| Kara Shumaker | Reviewer/Staff | X | | |
| Michelle N Small, MPH | Reviewer/Staff | X | | |

FACULTY DISCLOSURE INFORMATION

| | | | | |
|-----------------------------------|----------------------------------|--|---|---|
| <p>Angeles Alvarez-Secord, MD</p> | <p>Reviewer/Edu-Chair</p> | | <p>AZ, Abbvie; Aravive; Clovis, Eisai, Ellipses Pharma, Roche/Genentec ; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Gilead; Oncoquest/Canaria Bio</p> | <p>Research funds to institution (AZ, Abbvie; Aravive; Clovis; Eisai; Ellipses Pharma; Roche/Genentec; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana; Seagen; VBL Therapeutics; Zentalis; Oncoquest/Canaria Bio) Adboard (Abbvie) Uncomp AdBoard (Gilead; Oncoquest/Canaria Bio; Aravive; VBL) SteeringCommitte (Aravive; VBL; Oncoquest/Canaria Bio) Stock (Amgen; Johnson&Johnson)</p> |
|-----------------------------------|----------------------------------|--|---|---|